Liquidia Corporation received an additional $50 million from Healthcare Royalty/HCRx, accelerating the commercial launch of YUTREPIA after a favorable court ruling. Liquidia received a total of $175 million out of a potential $200 million from HCRx. An additional $25 million may become available if net sales of YUTREPIA exceed $100 million by 2026. The funds will be used to accelerate the commercial launch of YUTREPIA, an inhaled dry-powder formulation of treprostinil designed using Liquidia’s proprietary PRINT technology. United Therapeutics Corp. had requested a preliminary injunction and temporary restraining order against Liquidia. Liquidia is a biopharmaceutical company that develops, manufactures, and commercializes products for unmet patient needs in the US. United Therapeutics Corp. is a biotechnology company that develops and commercializes products for patients with chronic and life-threatening diseases.

Read more at Yahoo Finance: Liquidia Receives $50M from HCRx, Accelerates YUTREPIA’s Commercial Launch Following Favorable Court Ruling